CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. officer David J. Foehr reported a proposed sale of 862 common shares, with an aggregate market value of $16,205.60 and an approximate sale date of May 22, 2026. The shares were acquired from the issuer through restricted stock vesting on May 20, 2026, as compensation. The notice lists September 4, 2025, as the plan-adoption or instruction date for a Rule 10b5-1 plan, if relied upon.
Ceribell, Inc. officer David J. Foehr reported a proposed sale of 987 common shares, with an aggregate market value of $17,761.95 and an approximate sale date of May 21, 2026. The shares were acquired from the issuer through restricted stock vesting on May 20, 2026, as compensation. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Ceribell, Inc. officer Raymond Woo reported a proposed sale of 1,966 common shares, with an approximate sale date of May 21, 2026 and an aggregate market value of $35,379.94. He acquired the shares through restricted stock vesting on May 20, 2026. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Ceribell, Inc. officer and director Xingjuan Chao reported a proposed sale of 6,030 common shares at an approximate sale date of May 21, 2026, with an aggregate market value of $108,515.27. The shares were acquired through restricted stock vesting on May 20, 2026. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
The listed prior sales were 2,084 shares on February 23, 2026, and 39,000 shares each on March 3, April 6, and May 5, 2026.
Ceribell, Inc. (CBLL) names officer Joseph Manni in a notice to sell 1,378 common shares, with an aggregate market value of $24,798.35 and an approximate sale date of May 21, 2026. The remarks say the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. Joseph Manni also reported selling 768 common shares on February 23, 2026, for gross proceeds of $15,202.18.
Ceribell, Inc. officer Scott E. Blumberg reported a proposed sale of 1,387 common shares, with an aggregate market value of $24,960.31 and an approximate sale date of May 21, 2026. The shares were acquired from the issuer through restricted stock vesting on May 20, 2026, as compensation. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. During the prior three months, Scott E. Blumberg sold 808 common shares for gross proceeds of $15,993.96. Jennifer Ruchti signed as a duly authorized representative of Fidelity Brokerage Services LLC and attorney-in-fact for Scott E. Blumberg.
CeriBell, Inc. reports a Schedule 13G/A filing by The Global Value Investment Portfolio Management Pte Ltd and affiliated reporting persons.
The filing states beneficial ownership of 1,572,146 shares of Common Stock, equal to 4.2% of the class based on 37,859,680 shares outstanding as of March 31, 2026. The shares are held by u.life fund and none are held by GVIP Ventures SPC-SP3. The filing attributes shared voting and shared dispositive power of 1,572,146 shares to the reporting persons through The Global Value Investment Portfolio Management Pte Ltd and notes Caroline Kwong as Managing Director. Signature dates appear as May 14, 2026.
CeriBell, Inc. reported beneficial ownership information for Xingjuan Chao as of March 31, 2026. The filing shows 1,524,907 shares of Common Stock with sole voting power and shared voting power of 369,088, representing 4.9% of the class.
The filing states 37,859,520 shares outstanding as of March 31, 2026. It also discloses 826,328 shares issuable upon exercise of options exercisable within 60 days and 5,684 RSUs vesting within 60 days. The report is signed by Chao in her capacity as President and CEO.
CeriBell, Inc. reported strong top-line growth but wider losses for the quarter ended March 31, 2026. Revenue rose 29% year over year to $26.5 million, driven evenly by product sales of Wearables at $20.2 million and subscription revenue of $6.3 million. Gross margin remained high at 87%, reflecting the scalable nature of its model.
Operating expenses increased 36% to $43.9 million, mainly from higher headcount across functions and significant legal spending tied to an intellectual property enforcement matter, leading to a net loss of $19.7 million versus $12.8 million a year earlier, or ($0.52) per share. EBITDA was a loss of $20.5 million, and Adjusted EBITDA, which excludes stock-based compensation and specified IP litigation costs, was a loss of $11.2 million.
CeriBell ended the quarter with $141.2 million in cash, cash equivalents, and marketable securities and $20.0 million of term debt outstanding. Management believes this liquidity, together with expected cash from customers, can fund planned operations and capital needs for at least the next 12 months.
Ceribell, Inc. reported strong first quarter 2026 growth but wider losses. Total revenue was $26.5 million, up 29% from $20.5 million a year earlier, driven by both product and subscription growth, and gross margin remained high at 87%. The company ended the quarter with 680 active accounts and launched neonate and pediatric products after a successful pilot. Net loss widened to $19.7 million, or $0.52 per share, compared with a $12.8 million loss, as operating expenses rose to $43.9 million on commercial investments, added headcount, and IP litigation costs. Adjusted EBITDA loss was $11.2 million. Ceribell held $141.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and raised its 2026 revenue guidance to $112–$116 million, implying approximately 26%–30% growth over the prior year.